Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytodyn Inc (OP:CYDY)

0.3459 UNCHANGED
Streaming Delayed Price Updated: 3:58 PM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytodyn Inc

< Previous 1 2 3 4 5 Next >
News headline image
Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn Research Paper on Leronlimab Published in Frontiers in Immunology Journal
From CytoDyn Inc.
Via Business Wire
News headline image
Health Canada Authorizes Emergency Use of Leronlimab for Treatment of First Triple-Negative Breast Cancer Patient in Canada
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn Inc. Announces Adjournment of Annual Meeting of Shareholders to November 24, 2021 Due to Lack of Quorum
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn Announces Delaware Court Has Denied Activist Group’s Motion to Prevent Annual Meeting from Taking Place
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn Alerts Shareholders to Vote on Company’s Proxy Card Ahead of October 28th Annual Meeting
From CytoDyn Inc.
Via Business Wire
News headline image
Group of CytoDyn Stockholders Comments on Delaware Court Decision
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
News headline image
Delaware Court Agrees with CytoDyn that Activist Group’s Nominations are Invalid
From CytoDyn Inc.
Via Business Wire
News headline image
These OTC Markets Securities had the Most Trading Activity in September ↗
Photo by Annie Spratt on Unsplash As the 3rd quarter came to a close in September, the OTC Markets saw a slight decrease in total trading volume even as companies reported... 
Via Benzinga
News headline image
CytoDyn Comments on Rosenbaum/Patterson Activist Group “Plan”
From CytoDyn Inc.
Via Business Wire
News headline image
Group of CytoDyn Stockholders Releases White Paper Regarding Company’s Extremely Unfavorable Borrowing Practices
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
News headline image
CytoDyn to Present at Emerging Growth Conference on September 29 Followed by Live Q/A
From CytoDyn Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
News headline image
Group of CytoDyn Stockholders Shares Strategic Plan to Obtain Cancer Therapy Approval for Leronlimab
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
Accelerated Development of COVID-19 Vaccines to Combat Potential for Possible Future Viral Pathogens and Variants
Via FinancialNewsMedia
News headline image
CytoDyn Receives Clearance from Brazil’s FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week)
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at the World Antiviral Congress 2021
From CytoDyn Inc.
Via Business Wire
News headline image
Group of CytoDyn Stockholders Announces Federal Court Dismisses Litigation Brought by Company
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
News headline image
CytoDyn Announces Resolution of Federal Litigation with Rosenbaum/Patterson Activist Group
From CytoDyn Inc.
Via Business Wire
News headline image
Bruce Patterson, M.D., Director Candidate for CytoDyn Board, Presents at International COVID Summit
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
News headline image
Glancy Prongay & Murray LLP Announces Investigation of CytoDyn Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Group of CytoDyn Stockolders Responds to Misleading Company News Release
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
News headline image
CytoDyn Highlights Court Ordering Rosenbaum/Patterson Group to Comply With the Federal Securities Laws
From CytoDyn Inc.
Via Business Wire
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients
Via FinancialNewsMedia
News headline image
Group of CytoDyn Stockholders Warns Stockholders of Board’s Continued Value Destruction and Failures
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
News headline image
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
News headline image
Group of CytoDyn Stockholders Files Lawsuit to Force Company to Allow Stockholders to Vote for Alternative Director Nominees
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
News headline image
CytoDyn Urges Shareholders to Ignore Proxy Cards from Rosenbaum/Patterson Group
From CytoDyn
Via Business Wire
News headline image
Group of CytoDyn Stockholders Responds to Highly Misleading Company Release
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
News headline image
CytoDyn Provides Update on Rosenbaum/Patterson Group Litigation
From CytoDyn Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.